Group 1 - AirSculpt Technologies, Inc. will participate in the Sidoti Micro Cap Conference virtually on August 20-21, 2025, with a presentation scheduled for 10:00am ET on August 20 [1] - The presentation will be available for live webcast and archived for 90 days [1] Group 2 - AirSculpt offers a next-generation body contouring treatment that is minimally invasive, designed to remove fat and tighten skin while allowing for quick healing and minimal bruising [2] - The procedure aims to provide precise results in sculpting targeted areas of the body [2]

MIAMI BEACH, Fla., Aug. 01, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)("AirSculpt" or the "Company"), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2025. The Company also announced that Dennis Dean intends to retire from his position of Chief Financial Officer. Mr. Dean will retain his role until a permanent successor is in place. First Six Months 2025 Results 2025 Outlook The Company is affirming its full ye ...

Core Viewpoint - AirSculpt Technologies, Inc. has successfully completed a common stock offering, generating net proceeds of approximately $13.8 million, which will be used to prepay $10 million of its outstanding term loan debt, enhancing its capital structure and financial flexibility [1][2]. Financial Performance - The company has prepaid $10 million of its outstanding debt, improving its capital structure [1][2]. - After the stock offering, AirSculpt has 62,436,670 shares of common stock outstanding [2]. - The company retains full availability of $5 million under its revolving credit facility after making a remaining payment of $2.9 million on June 16, 2025 [2]. Strategic Initiatives - The prepayment of debt is part of the company's strategy to advance its transformation and position itself for sustained long-term growth in revenue and profitability [2]. - The company does not anticipate the need for additional material capital raises this year, assuming no significant changes in the macroeconomic environment [1]. Product Offering - AirSculpt provides a next-generation body contouring treatment that is minimally invasive, designed to optimize comfort and precision, allowing for quick healing with minimal bruising and precise results [3].

Core Viewpoint - AirSculpt Technologies, Inc. has successfully closed a public offering of 3,160,000 shares of common stock, with an additional 474,000 shares purchased by the underwriter, resulting in estimated proceeds of approximately $13.8 million after expenses [1][2]. Group 1: Offering Details - The public offering was underwritten by Leerink Partners, who acted as the sole bookrunner [2]. - The majority of the net proceeds from the offering will be used for prepaying a portion of the Company's outstanding debt under its existing credit agreement, while the remainder will be allocated for general corporate purposes, including working capital and other business opportunities [2]. Group 2: Regulatory Information - A shelf registration statement for the shares was filed with the Securities and Exchange Commission (SEC) and became effective on March 24, 2025 [3]. - A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are accessible on the SEC's website [3]. Group 3: Company Overview - AirSculpt is a provider of next-generation body contouring treatments, focusing on comfort and precision, with procedures designed to remove fat and tighten skin while allowing for quick healing and minimal bruising [5].

Core Viewpoint - AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of common stock priced at $3.80 per share, aiming to raise $12.0 million before expenses [1][2]. Group 1: Offering Details - The company has granted the underwriter a 30-day option to purchase up to 474,000 additional shares at the same price [1]. - The offering is expected to close on or about June 11, 2025, subject to customary closing conditions [1]. Group 2: Use of Proceeds - A majority of the net proceeds from the offering will be used for the prepayment of a portion of the company's outstanding indebtedness under its existing credit agreement [2]. - The remainder of the net proceeds will be allocated for general corporate purposes, including working capital and other business opportunities [2]. Group 3: Company Overview - AirSculpt is a provider of next-generation body contouring treatments designed for comfort and precision, focusing on minimally invasive procedures that remove fat and tighten skin [5].

Core Viewpoint - AirSculpt Technologies, Inc. has announced a public offering of 3,160,000 shares of its common stock, with an additional option for underwriters to purchase up to 474,000 shares [1][2]. Group 1: Offering Details - The public offering consists of 3,160,000 shares of common stock, with a 30-day option for underwriters to buy an additional 474,000 shares [1]. - Vesey Street Capital Partners, the largest stockholder, is interested in purchasing up to $4.0 million in shares from the offering [2]. - Leerink Partners is acting as the sole bookrunner for the offering [3]. Group 2: Use of Proceeds - A portion of the net proceeds from the offering will be used to prepay part of the Company's outstanding debt under its existing credit agreement [3]. - The remaining proceeds will be allocated for general corporate purposes, including working capital and other business opportunities [3]. Group 3: Regulatory Information - A shelf registration statement for the shares was filed with the Securities and Exchange Commission and became effective on March 24, 2025 [4].

Core Insights - AirSculpt Technologies, Inc. reported first-quarter results for 2025, indicating a focus on returning to growth through strategic initiatives and cost management [1][2]. Financial Performance - Case volume for Q1 2025 was 3,076, a decline of 17.9% from 3,746 in Q1 2024 [6][22]. - Revenue decreased by 17.3% to $39.4 million from $47.6 million in the same quarter of the previous year [6][17]. - The company reported a net loss of $2.8 million compared to a net income of $6.0 million in Q1 2024 [6][17]. - Adjusted EBITDA was $3.8 million, down from $7.3 million in Q1 2024, with an adjusted EBITDA margin of 9.5% compared to 15.4% [6][22]. Strategic Initiatives - The CEO expressed confidence in the company's transformation efforts and highlighted the early benefits from a new go-to-market strategy, which has improved lead volumes and revenue decline [2]. - The company is focusing on increasing lead generation, consultations, and case conversions through enhanced marketing and sales efforts [2]. - AirSculpt is piloting a standalone skin tightening service, which has garnered increasing interest, positioning the company to capitalize on this opportunity [2]. Liquidity and Cash Flow - As of March 31, 2025, the company had $5.6 million in cash and cash equivalents, down from $8.2 million at the end of 2023 [5][19]. - Operating cash flow for Q1 2025 was $0.9 million, a decrease from $3.4 million in Q1 2024 [5][21]. 2025 Outlook - The company projects full-year 2025 revenue between $160 million and $170 million, with adjusted EBITDA guidance of approximately $16 million to $18 million [4][6].